Last reviewed · How we verify
Sizofilan (SIZOFIRAN)
Sizofilan (generic name: SIZOFIRAN) is a drug. It is currently in Phase 2 development.
Sizofilan is a small molecule that works by interacting with a specific target in the body to produce a therapeutic effect.
Sizofilan, also known as Sonifilan, is being studied in clinical trials for its potential impact on the quality of life in patients with cervical cancer. The exact mechanism of Sizofilan is currently unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SIZOFIRAN |
|---|---|
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine Sizofilan as a key that fits into a lock in the body. When it binds to this lock, it triggers a series of events that ultimately lead to the desired therapeutic outcome. This process is highly specific and allows Sizofilan to target the underlying cause of a particular disease or condition.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sizofilan CI brief — competitive landscape report
- Sizofilan updates RSS · CI watch RSS
Frequently asked questions about Sizofilan
What is Sizofilan?
How does Sizofilan work?
What is the generic name of Sizofilan?
What development phase is Sizofilan in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing